Transporter

Noradrenaline transporter

Sodium-dependent noradrenaline transporter

The noradrenaline transporter takes noradrenaline back up into the nerve cell, which ends part of its action. The human transporter was cloned by expression, it needs sodium, and its messenger RNA is found in the brainstem and the adrenal gland.1,2 A single gene on chromosome 16, called SLC6A2, codes for it, and alternative splicing of its messenger RNA gives different forms. Decreased expression of the transporter has been reported in depression and in autonomic dysfunction.3

In the adult rat brain, antibodies labelled the cell bodies, axons and dendrites of noradrenergic neurons, with extensive branches in the hippocampus and the cortex, but not neurons that make adrenaline or dopamine. In the cell bodies the label was inside the cell and absent from the plasma membrane. Electron microscopy in the prelimbic prefrontal cortex also found much of the protein inside axon terminals, which fits the idea that the trafficking of the transporter regulates clearance. Some adrenal chromaffin cells were labelled as well.4 In human postmortem brain, an antiserum against the N-terminus of the transporter recognised a band of 80 kDa in the cortex. In the left insular cortex of people who died of cocaine, the number of binding sites for nisoxetine and the amount of transporter protein were higher than in drug-free controls, while the right insula was unchanged.3

Measured at the human transporters, fourteen antidepressants bound it more strongly than the serotonin transporter, among them all tricyclic antidepressants of the secondary amine type.5 Atomoxetine, a selective inhibitor of the noradrenaline transporter used in ADHD, bound the human noradrenaline, serotonin and dopamine transporters with Ki values of 5, 77 and 1451 nM. In rats it raised noradrenaline in the prefrontal cortex three times, and it also raised dopamine there three times, but it did not change dopamine in the striatum or the nucleus accumbens. Methylphenidate raised dopamine in these two regions as much as in the cortex. The authors suggest that, unlike methylphenidate, atomoxetine would not have motor or drug abuse liabilities, because it does not raise dopamine in the striatum or the accumbens.6 In rat brain tissue, amphetamine-type stimulants such as amphetamine, methamphetamine and MDMA released noradrenaline more potently than dopamine.7

The transporter also clears dopamine, and in the frontal cortex it is the main route. Dopamine uptake into frontal cortex nerve terminals of normal mice was inhibited by nisoxetine but not by a DAT inhibitor, and nisoxetine had no effect in mice without the noradrenaline transporter. At its highest dose, cocaine was 70 percent less effective at blocking this uptake in the knockout mice.8

Mice without the transporter clear noradrenaline more slowly, behave in a classic antidepressant test like mice treated with antidepressants, and are more strongly stimulated by cocaine and amphetamine.2 In regions rich in noradrenaline, the knockout mice had 55 to 70 percent less noradrenaline in the tissue and a clearance of released noradrenaline at least six times slower, and the level outside the cells was twice as high. The postsynaptic alpha-1 receptor was downregulated in their hippocampus.9

Sources (9)
  1. Pacholczyk et al. 1991Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter Nature
  2. Xu et al. 2000Xu F, Gainetdinov RR, Wetsel WC, et al. (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants Nat Neurosci
  3. Mash et al. 2005Mash DC, Ouyang Q, Qin Y, et al. (2005) Norepinephrine transporter immunoblotting and radioligand binding in cocaine abusers J Neurosci Methods
  4. Schroeter et al. 2000Schroeter S, Apparsundaram S, Wiley RG, et al. (2000) Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter J Comp Neurol
  5. Tatsumi et al. 1997Tatsumi M, Groshan K, Blakely RD, et al. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters Eur J Pharmacol
  6. Bymaster et al. 2002Bymaster FP, Katner JS, Nelson DL, et al. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology
  7. Rothman et al. 2001Rothman RB, Baumann MH, Dersch CM, et al. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse
  8. Morón et al. 2002Morón JA, Brockington A, Wise RA, et al. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines J Neurosci
  9. Torres et al. 2003Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function Nature Reviews Neuroscience

Binding affinity (Kᵢ)

20 substances, 32 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

17 measurements
  • α-PVP60 nMRickli et al. 2015
    Assay
    cloned NET receptor or transporter binding (HEK293 cell membranes)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 20 SD
  • AmphetamineAgonistdepends on assay70 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing human NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 10 SEM, n = 4

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 70–1000 nM.

  • Methylphenidate100 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing human NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 10 SEM, n = 4
  • MDPV107 nMEshleman et al. 2013 · 2 reports
    Assay
    HEK-293 cells expressing human NET, [125I]RTI-55 displacement
    Shown value from
    Eshleman et al. 2013, Table 2
    Range
    80–107 nM in 2 reports
    Error
    ± 34 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Simmler et al. 201380 nMTable 1
    Eshleman et al. 2013107 nMTable 2
  • MDMAAgonist1190 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing human NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 130 SEM, n = 4
  • 6-APBAgonist1800 nMRickli et al. 2015
    Assay
    cloned NET receptor or transporter binding (HEK293 cell membranes)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 400 SD
  • MethamphetamineAgonistother reports differ1820 nMEshleman et al. 2017 · 4 reports
    Assay
    [125I]RTI-55 radioligand binding inhibition at human NET in HEK293 cells
    Shown value from
    Eshleman et al. 2017, Table 1
    Range
    1390–4280 nM in 4 reports
    Error
    ± 230 SEM, n = 19

    This is the best-supported value. Other reports differ. 5 reports in all, 110–4280 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Simmler et al. 20134280 nMTable 1
    Eshleman et al. 20171820 nMTable 1
    Eshleman et al. 20141480 nMTable 3
    Eshleman et al. 20131390 nMTable 2
  • Cocaineother reports differ1910 nMEshleman et al. 2017 · 9 reports
    Assay
    [125I]RTI-55 radioligand binding inhibition at human NET in HEK293 cells
    Shown value from
    Eshleman et al. 2017, Table 1
    Range
    410–4470 nM in 9 reports
    Error
    ± 230 SEM, n = 25

    This is the best-supported value. Other reports differ. 11 reports in all, 246–4470 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Simmler et al. 20134470 nMTable 1
    Eshleman et al. 20171910 nMTable 1
    Eshleman et al. 20181880 nMTable 3
    Janowsky et al. 2014410 nMTable 4
    Eshleman et al. 20141280 nMTable 3
    Andersen et al. 2015925 nMSupporting Table S3
    Eshleman et al. 20131380 nMTable 2
    Carroll et al. 2009830 nMTable 1
  • 5-MeO-DMT2859 nMRay 2010
    Assay
    PDSP receptorome (compiled; species not stated per entry, predominantly human clones)
    Shown value from
    Ray 2010, Table S2 (AllKiData)
  • 5-APBAgonist3100 nMRickli et al. 2015
    Assay
    cloned NET receptor or transporter binding (HEK293 cell membranes)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 200 SD
  • CathinoneAgonist3500 nMSimmler et al. 2013
    Assay
    Radioligand displacement binding in HEK293-cell membranes expressing human NET
    Shown value from
    Simmler et al. 2013, Table 1
    Error
    ± 2700 SD
  • LSD5600 nMEshleman et al. 2014 · 2 reports
    Assay
    HEK-hNET cells; [125I]RTI-55 binding
    Shown value from
    Eshleman et al. 2014, Table 3
    Error
    ± 260 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Janowsky et al. 20145600 nMTable 4
    Eshleman et al. 20145600 nMTable 3
  • DMTAgonist6500 nMRickli et al. 2016
    Assay
    HEK293 membranes expressing human NET; N-methyl-[3H]nisoxetine displacement
    Shown value from
    Rickli et al. 2016, Table 2
    Error
    ± 1300 SD
  • Bupropion6970 nMCarroll et al. 2009 · 2 reports
    Assay
    HEK cells expressing human NET, [125I]RTI-55 binding
    Shown value from
    Carroll et al. 2009, Table 1
    Error
    ± 2620 SEM
  • Butylone7980 nMEshleman et al. 2013 · 2 reports
    Assay
    HEK-293 cells expressing human NET, [125I]RTI-55 displacement
    Shown value from
    Eshleman et al. 2013, Table 2
    Range
    7980–8130 nM in 2 reports
    Error
    ± 550 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Simmler et al. 20138130 nMTable 1
    Eshleman et al. 20137980 nMTable 2
  • TapentadolInhibitorrange incl. untraced8800 nMTzschentke et al. 2007 · 2 reports
    Assay
    recombinant human monoamine transporter binding assay
    Shown value from
    Tzschentke et al. 2007, Table 1
    Error
    ± 1170 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Tzschentke et al. 20078800 nMTable 1
    Roulet et al. 20218800 nMTable 1
  • 4-FMA9000 nMRickli et al. 2015
    Assay
    cloned NET receptor or transporter binding (HEK293 cell membranes)
    Shown value from
    Rickli et al. 2015, Table 2
    Error
    ± 600 SD

Mouse

5 measurements
  • AmphetamineAgonist120 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing mouse NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 20 SEM, n = 4
  • Methylphenidate170 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing mouse NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 30 SEM, n = 4
  • MethamphetamineAgonist190 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing mouse NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 50 SEM, n = 4
  • Cocaine460 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing mouse NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 60 SEM, n = 4
  • MDMAAgonist1750 nMHan et al. 2006
    Assay
    Uptake inhibition in Intestine 407 cells transiently expressing mouse NET
    Shown value from
    Han et al. 2006, Table 1
    Error
    ± 510 SEM, n = 4

Rat

7 measurements
  • MethamphetamineAgonist48 nMRothman et al. 2001
    Assay
    Rat brain synaptosomes (whole brain minus caudate and cerebellum), [3H]norepinephrine uptake inhibition, 10 min at 25 °C, RTI-229 5 nM
    Shown value from
    Rothman et al. 2001, Table V
    Error
    ± 5.1 SD, n = 3
  • EphedrineAgonist225 nMRothman et al. 2001
    Assay
    Rat brain synaptosomes (whole brain minus caudate and cerebellum), [3H]norepinephrine uptake inhibition, 10 min at 25 °C, RTI-229 5 nM
    Shown value from
    Rothman et al. 2001, Table V
    Error
    ± 36 SD, n = 3
  • Methylphenidate270 nMKim et al. 2007
    Assay
    rat cerebrum and brainstem membranes, [3H]nisoxetine displacement
    Shown value from
    Kim et al. 2007, Table 1
    Error
    ± 23 SEM
  • MDMAAgonist462 nMRothman et al. 2001
    Assay
    Rat brain synaptosomes (whole brain minus caudate and cerebellum), [3H]norepinephrine uptake inhibition, 10 min at 25 °C, RTI-229 5 nM
    Shown value from
    Rothman et al. 2001, Table V
    Error
    ± 18 SD, n = 3
  • TapentadolInhibitor480 nMTzschentke et al. 2007
    Assay
    rat synaptosomal monoamine reuptake assay
    Shown value from
    Tzschentke et al. 2007, Table 1
    Error
    ± 110 SEM
  • Cocaine779 nMRothman et al. 2001
    Assay
    Rat brain synaptosomes (whole brain minus caudate and cerebellum), [3H]norepinephrine uptake inhibition, 10 min at 25 °C, RTI-229 5 nM
    Shown value from
    Rothman et al. 2001, Table V
    Error
    ± 30 SD, n = 3
  • Tramadolsource not traced780 nMRoulet et al. 2021
    Assay
    noradrenaline uptake inhibition, compiled in a review table (original assay not restated)
    Shown value from
    Roulet et al. 2021, Table 1

Unspecified

3 measurements
  • Cocaine500 nMFroimowitz et al. 2007 · 2 reports
    Assay
    [125I]RTI-55 binding at the NET
    Shown value from
    Froimowitz et al. 2007, Table 1
    Range
    500–1990 nM in 2 reports
    Error
    ± 90 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Froimowitz et al. 2007500 nMTable 1
    Carroll et al. 20041990 nMTable 1
  • Methylphenidate660 nMFroimowitz et al. 2007
    Assay
    [125I]RTI-55 binding at the NET
    Shown value from
    Froimowitz et al. 2007, Table 1
    Error
    ± 50 SEM
  • Ephenidine841 nMKang et al. 2017
    Assay
    NIMH PDSP radioligand binding, [3H]nisoxetine (0.5 nM), species not stated
    Shown value from
    Kang et al. 2017, Results (NIMH PDSP secondary assay, Table 1 not in the supplied PDF)

Functional potency (EC₅₀)

14 substances, 18 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

4 measurements
  • MethamphetamineAgonist125 nMEshleman et al. 2017 · 3 reports
    Assay
    Release of preloaded [3H]neurotransmitter from HEK293 cells expressing human NET
    Shown value from
    Eshleman et al. 2017, Table 3
    Range
    67–128 nM in 3 reports
    Error
    ± 24 SEM, n = 8
    Emax
    102.6 ± 3.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Eshleman et al. 2017125 nMTable 3
    Eshleman et al. 201467 nMTable 3
    Eshleman et al. 2013128 nMTable 3
  • MDMAAgonist360 nMEshleman et al. 2017 · 2 reports
    Assay
    Release of preloaded [3H]neurotransmitter from HEK293 cells expressing human NET
    Shown value from
    Eshleman et al. 2017, Table 3
    Range
    360–570 nM in 2 reports
    Error
    ± 92 SEM, n = 7
    Emax
    147.0 ± 15.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Eshleman et al. 2017360 nMTable 3
    Eshleman et al. 2013570 nMTable 3
  • MephedroneAgonist410 nMEshleman et al. 2013
    Assay
    HEK-293 cells expressing human NET, release of preloaded [3H]noradrenaline
    Shown value from
    Eshleman et al. 2013, Table 3
    Error
    ± 130 SEM, n = 6
    Emax
    152.0 ± 32.0%
  • MethyloneAgonist426 nMEshleman et al. 2013
    Assay
    HEK-293 cells expressing human NET, release of preloaded [3H]noradrenaline
    Shown value from
    Eshleman et al. 2013, Table 3
    Error
    ± 67 SEM, n = 4
    Emax
    122.0 ± 32.0%

Rat

14 measurements
  • MethamphetamineAgonist11 nMNagai et al. 2007 · 4 reports
    Assay
    rat brain synaptosome monoamine release
    Shown value from
    Nagai et al. 2007, Table 3
    Range
    11–14 nM in 4 reports
    Error
    ± 2.9 SD, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Fitzgerald et al. 202413 nMTable 1
    Nagai et al. 200711 nMTable 3
    Rothman et al. 200312 nMTable 1
    Baumann et al. 201214 nMTable 1
  • CathinoneAgonist12 nMRothman et al. 2003 · 2 reports
    Assay
    rat brain synaptosomes, release of [3H]NE
    Shown value from
    Rothman et al. 2003, Table 1
    Range
    12–26 nM in 2 reports
    Error
    ± 0.70 SD, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Fitzgerald et al. 202426 nMTable 1
    Rothman et al. 200312 nMTable 1
  • 6-APBAgonist14 nMBrandt et al. 2020
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Brandt et al. 2020, Table 1
    Error
    ± 2.0 SD, n = 3
    Emax
    98.0%
  • 5-APBAgonist21 nMBrandt et al. 2020
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Brandt et al. 2020, Table 1
    Error
    ± 4.0 SD, n = 3
    Emax
    103.0%
  • AmphetamineAgonistunresolved22 nMFitzgerald et al. 2024 · 2 reports
    Assay
    Monoamine release in rat brain synaptosomes
    Shown value from
    Fitzgerald et al. 2024, Table 1
    Range
    7.1–22 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 7.1–22 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Fitzgerald et al. 202422 nMTable 1
    Rothman et al. 20037.1 nMTable 1
  • 5-MAPBAgonist24 nMBrandt et al. 2020
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Brandt et al. 2020, Table 1
    Error
    ± 3.0 SD, n = 3
    Emax
    99.0%
  • 4-FAAgonist37 nMNagai et al. 2007
    Assay
    rat brain synaptosome monoamine release
    Shown value from
    Nagai et al. 2007, Table 3
    Error
    ± 8.9 SD, n = 3
  • EphedrineAgonist43 nMRothman et al. 2003
    Assay
    rat brain synaptosomes, release of [3H]NE
    Shown value from
    Rothman et al. 2003, Table 1
    Error
    ± 4.0 SD, n = 3
  • MDAAgonist47 nMBrandt et al. 2020
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Brandt et al. 2020, Table 1
    Error
    ± 7.0 SD, n = 3
    Emax
    91.0%
  • MephedroneAgonist63 nMWalther et al. 2019 · 3 reports
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Walther et al. 2019, Table 1 (4-Me row)
    Range
    63–83 nM in 3 reports
    Error
    ± 16 SD, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Walther et al. 201963 nMTable 1 (4-Me row)
    Chojnacki et al. 202383 nMTable 1
    Baumann et al. 201263 nMTable 1
  • MDMAAgonist90 nMBrandt et al. 2020 · 3 reports
    Assay
    Transporter-mediated monoamine release in rat brain synaptosomes
    Shown value from
    Brandt et al. 2020, Table 1
    Range
    54–90 nM in 3 reports
    Error
    ± 13 SD, n = 3
    Emax
    99.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Brandt et al. 202090 nMTable 1
    Nagai et al. 200786 nMTable 3
    Baumann et al. 201254 nMTable 1
  • PseudoephedrineAgonist224 nMRothman et al. 2003
    Assay
    rat brain synaptosomes, release of [3H]NE
    Shown value from
    Rothman et al. 2003, Table 1
    Error
    ± 14 SD, n = 3
  • MethyloneAgonist270 nMGlatfelter et al. 2021 · 3 reports
    Assay
    rat brain synaptosomes, release of [3H]norepinephrine
    Shown value from
    Glatfelter et al. 2021, Table 1
    Range
    93–270 nM in 3 reports
    Error
    ± 70 SD, n = 3
    Emax
    98.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Nagai et al. 200793 nMTable 3
    Glatfelter et al. 2021270 nMTable 1
    Baumann et al. 2012152 nMTable 1
  • DMTAgonist4166 nMBlough et al. 2014
    Assay
    rat brain synaptosomes; [3H]norepinephrine release
    Shown value from
    Blough et al. 2014, Table 1
    Error
    ± 317 SD, n = 3

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.